Physician profile
Richard E Edwards
NPI 1003059403
$5,909.85
in general payments reported to CMS, 2019-2025
26 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,648 · 2020: $2,578 · 2021: $479 · 2022: $362 · 2023: $414 · 2024: $198 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $747.75 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,078.54 | 2019-2025 | |
| Abbvie INC. | $511.82 | 2021-2025 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.33 | 2022-2024 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $251.10 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $114.78 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $101.49 | 2022-2025 | Qelbree |
| Intuitive Surgical, INC. | $90.91 | 2023 | Da Vinci Surgical System |
| Novo Nordisk INC | $76.49 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.69 | 2019-2022 | |
| Amgen INC. | $45.33 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $38.60 | 2023-2024 | Gemtesa |
| Kyowa Kirin, INC. | $31.86 | 2024 | Crysvita |
| Glaxosmithkline, LLC. | $24.81 | 2019-2020 | |
| Lilly USA, LLC | $24.68 | 2019-2021 | |
| Tactile Systems Technology INC | $23.80 | 2025 | Nimbl, Flexitouch Plus |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $16.19 | 2023 | Seglentis |
| Allergan, INC. | $15.64 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.43 | 2021 | |
| Biomerieux INC | $13.04 | 2021 | |
| Biofire Diagnostics, LLC | $13.04 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.03 | 2019 | |
| Shire North American Group INC | $12.77 | 2019 | |
| Esperion Therapeutics, INC. | $12.62 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $12.24 | 2021 | |
| Adlon Therapeutics L.P. | $12.03 | 2021 | |
| Abbott Laboratories | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.